belgium is world-class for biopharmaceutical r&d ......(zew innovation indicator, 2015) ......
TRANSCRIPT
Belgium is world-class for biopharmaceutical R&D, manufacturing and logistics
FlyPharma Conference, Brussels - 7th June 2016
Frank BeckxManaging Director essenscia vlaanderen
Executive summary
• The evidence: key facts & figures
• 5 reasons why Belgium is a key player
• Biopharma is building a stronger future in Belgium
Belgium is world-class for biopharmaceutical
R&D, manufacturing and logistics
2
Belgium: small country, great scientists
4 Nobel Prize Laureates for Physiology or Medicine
Corneille Heymans
(1892 - 1968)Christian De Duve
(1917 - 2013)
Jules Bordet
(1870 - 1961)Albert Claude
(1899 - 1983)
antigens and
antibodies in
immune reactions
role of sinus and
aortic mechanisms
in the regulation of
respiration
structural and
functional
organisation of
the cell
structural and
functional
organisation of
the cell
1919 1938 1974 1974
3
Belgium: small country, great scientists
A wide variety of renowned scientists in life sciences
Marc Van Montagu
(1933 - )
Paul Janssen
(1926 - 2003)
Peter Piot
(1949 - )
Paul Stoffels
(1962 - )
Jean-Jacques Cassiman
(1943 - )
Ferdinand Peeters
(1918 - 1998)
4
« Belgium in top 10 of the most innovative
pharma valleys worldwide » (Nature, 2010)
« Belgium has established itself as an especially
innovative country. It is characterized by a well-
functioning innovation system » (ZEW Innovation Indicator, 2015)
« 5 of the 100 essential medicines have been
developed in Belgian laboratories »(World Health Organisation
Model Lists of Essential Medicines)
International recognition
of Belgian biopharma
5
All top 10 global biopharmaceutical
companies have key activities in Belgium
0
5
10
15
20
25
30
35
40
45
50
Novartis Pfizer Roche Sanofi Merck & Co. Johnson &Johnson
GlaxoSmithKline AstraZeneca Gilead Sciences AbbVie
Top 10 biopharmaceutical companies worldwideRx sales (2014)
in billion USD
Major production facilities and R&D activity in Belgium
Clinical trial activities and sales office in Belgium
Source: PharmaExec.com (based on data from 2015 EvaluatePharma, Evaluate Ltd, www.evaluate.com)
6
Belgium, a key player in the European
biopharmaceutical industry
2%3%
6%
10%
13%
Population GDP Value added R&D-expenditures Export
Pharmaceutical industry
Belgian share in total EU-28
Source: Eurostat (2015) for population, GDP and export ; Eurostat National
Accounts (SEC 2010, 2013) for value added; R&D: EFPIA (2013 data) 7
Executive summary
• The evidence: key facts & figures
• 5 reasons why Belgium is a key player
• Biopharma is building a stronger future in Belgium
Belgium is world-class for biopharmaceutical
R&D, manufacturing and logistics
8
• Almost 2/3 of all pharma employeeshave a higher education degree
• Half of all researchers in the biopharma industry are women
• Multilingualism in Belgium is acompetitive advantage
• 4 pharmaceutical companies are in the top 5 of the most attractive employers in Belgium
• « One of the highest productivity rates in the world »(« The Conference Board » 2010)
A highly skilled and productive workforce
Source: National Bank of Belgium (Central Balance Sheet, 2014) ; Commission for federal cooperation, Working
group CFS/STAT; calculations Federal Science Policy Office
9
• 12 universities of which 3 in World Top 100 of Universities in Life Sciences (Academic Ranking of World Universities 2015)
• A high concentration of university hospitals
• Leading R&D centers of major companies
• A broad offering of science parks with incubation and innovation centers
• Highly specialised research institutes with international reputation in biotechnology
A unique innovation ecosystem that
accelerates groundbreaking R&D
10
The Belgian pharmaceutical industry
is highly R&D-intensive
0%
5%
10%
15%
20%
25%
30%
35%
R&D intensity (=R&D/production)Pharmaceutical industry
Source: EFPIA, 2013
11
The European leader in clinical trials
0
2
2
1
1
1
1
2
1
2
3
3
6
Italy
Germany
United Kingdom
Finland
France
Spain
Norway
Netherlands
Sweden
Austria
Switzerland
Denmark
Belgium
3
3
3
4
4
4
5
5
6
7
7
10
11
SOURCE: ClinicalTrial.gov; Worldbank
64
18
26
13
14
6
46
71
120
23
125
7
41
128
55
59
56
60
23
199
241
221
165
272
19
80
Phase 1 Phase 2
2012, # trials starting per million inhabitants x # of trials started
12
Belgian biopharma delivers medical
breakthroughs for worldwide diseases
13
HIV
Oncology
Rare diseases
Immunology TBC
MalariaCell therapy
Mental illnesses
A prominent location, an excellent
logistical and business infrastructure
• A strategic and central position at the political heart of
Europe
• Direct access to a potential EU market of 500 million
people
• A first-class logistical and business infrastructure
offering a direct export gate to the rest of the world
14
Belgium biopharma, a world presence:
second biggest exporter in the EU
Europe (including
Russia)57,7%
America25,0%
Asia11,9%
Africa3,9%
Australia & Oceania
1,5%
Top EU countries
based on pharma
export value
1. Germany
2 Belgium
3. UK
4. Ireland
5. France
Belgium’s export of pharmaceuticals (2015): 38.8 billion €
Source : Eurostat based on Chapter 30 of the Harmonised
System (HS2)
Source : National Bank of Belgium according to the EU-concept
(including international distribution centers & transit activities)
Almost half of pharmaceutical products are exported outside Europe
15
Belgium
Netherlands
Switzerland
France
UK
Germany
Italy
W-Europe
Belgium has experienced particularly fast
growth in pharmaceutical export by air cargo
Index (2000=100%)
16
A first-class infrastructure
for life sciences logistics
• 2 pharma logistics hubs in Belgium
• Both airport communities are certified by IATA as
a Centre of Excellence for Pharmaceuticals (CEIV Pharma)
• Belgium, a forerunner in developing
a worldwide standard for pharma handling
• Brussels Airport was the first certified airport
community in the world
• Pharma logistics is driven by temperature control
throughout the transportation chain
17
Belgium biopharma plays a leading
role in the fight against ebola
1976
Aug
2014
Dec
2013
Jan
2015
Oct
2015
Sep-Oct
2014
Mar
2014
Belgian
scientist
Peter Piot
discovers
ebola virus
Severe
outbreak in
Guinea,
Liberia &
Sierra Leona
GSK & Janssen
Pharmaceutica
accelerate
development
of candidate
vaccines in
Belgian labs
Janssen
Pharmaceutica
starts clinical
trials in Liberia
to prevent
further
outbreaks
First case
of current
strain of
ebola in
West-Africa
WHO
declares
epidemic
to be of
international
concern
GSK ships
first batch of
vaccines to
Liberia from
Brussels
Airport
18
1. A highly qualified and productive workforce
2. A unique academic and industrial network
3. A strong focus on innovative research to develop the
therapies of the future for patients around the globe
4. A prominent location in the heart of Europe
5. A state-of-the-art logistics platform to export worldwide
5 reasons why Belgium is
a key player in biopharma
19
Executive summary
• The evidence: key facts & figures
• 5 reasons why Belgium is a key player
• Biopharma is building a stronger future in Belgium
Belgium is world-class for biopharmaceutical
R&D, manufacturing and logistics
20
The biopharmaceutical industry,
a growing sector in Belgium
Source:
Employment: National Social Security Office - decentralised statistics (number of jobs on 30th June); 2015 = estimate based
on centralised statistics ;
Export: National Bank of Belgium according to the Communautarian concept (including distribution centers & transit activities)
R&D: based on latest data from Commission for federal cooperation, Working group CFS/STAT; calculations Federal Science
Policy Office ; Intramural expenditures – product group approach
21050
26454
2005 2015
Employment(number of jobs)
+26%
27
39
2005 2015
Export (in billion €)
+46%
Over the past 10 years, the biopharmaceutical industry
has become a key pillar of the Belgian economy
21
921
2293
2005 2013
R&D-expenditures(in million €)
+149%
Janssen Pharmaceutica (Beerse)
Launch of new incubator JLINX
Sanofi Genzyme (Geel)
Extension production capacity
& new lab
Pfizer (Puurs)
New vaccine production unit
Recent investments in the
Belgian life sciences industry
Datwyler (Alken)
State-of-the-art mixing hall
for pharmaceutical packaging
22
Alcon (Puurs)
Expansion of production lines
Baxalta (Lessines)
Investment in production of
immunoglobulin for the
treatment of immune deficiency
MaSTherCell (Gosselies)
Extension production capacity for
cell therapy
GSK (Wavre)
Modernisation of production unit for
vaccines against hepatitis A
Bone Therapeutics & Promethera
(Gosselies)
Pilot plant for cell therapy
23
Recent investments in the
Belgian life sciences industry
UCB (Braine-L’Alleud)
Biotechnology pilot plant
• A competitive R&D tax environment, including:
• 80% patent income reduction
• Tax incentives for employing scientific researchers
• High Level Group
‘Chemistry and life sciences’
between essenscia & the federal
government initiated by the
Belgian Prime Minister (2015)
• Structural dialogue between essenscia and the
regional Flemish and Walloon governments with
strong focus on innovation and labour market
The authorities support a strong future
for pharmaceutical activity in Belgium
24
The Pact for the Future that was signed with
the federal government has three key pillars:
• an improved access to innovative therapies for the patient
• supporting growth and innovation within the industry
• providing a new deontological framework for the sector
A Pact for the Future to strengthen one of
the best healthcare systems in the world
25
Belgium is world-class for biopharmaceutical R&D, manufacturing and logistics
FlyPharma Conference, Brussels - 7th June 2016
Frank BeckxManaging Director essenscia vlaanderen